ProfileGDS5678 / 1435736_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 66% 66% 66% 69% 67% 66% 66% 66% 66% 66% 66% 66% 67% 66% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.0117666
GSM967853U87-EV human glioblastoma xenograft - Control 24.017866
GSM967854U87-EV human glioblastoma xenograft - Control 34.0078166
GSM967855U87-EV human glioblastoma xenograft - Control 44.2730169
GSM967856U87-EV human glioblastoma xenograft - Control 54.006267
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.0379566
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.0607666
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.9907866
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.0094466
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.0029966
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.9939266
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.9820666
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.1000967
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.0020666